Latest filings (excl ownership)
8-K
Patient screening underway in Ntrust-1, the first U.S.-based clinical trial of an engineered NK cell therapy for the treatment of lupus nephritis
27 Jun 24
8-K
Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors
13 Jun 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Nkarta Reports First Quarter 2024 Financial Results and Corporate Highlights
9 May 24
ARS
2023 FY
Annual report to shareholders
25 Apr 24
DEFA14A
Additional proxy soliciting materials
25 Apr 24
DEF 14A
Definitive proxy
25 Apr 24
PRE 14A
Preliminary proxy
15 Apr 24
8-K
Other Events
28 Mar 24
424B5
Prospectus supplement for primary offering
25 Mar 24
8-K
Regulation FD Disclosure
25 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Nkarta Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
21 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
S-8
Registration of securities for employees
3 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Nkarta Reports Third Quarter 2023 Financial Results and Corporate Highlights
9 Nov 23
8-K
Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis
17 Oct 23
8-K
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
16 Oct 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Nkarta Reports Second Quarter 2023 Financial Results and Corporate Highlights
10 Aug 23
8-K
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
5 Jul 23
8-K
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
27 Jun 23
8-K
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
26 Jun 23
8-K
Amendments to Articles of Incorporation or Bylaws
9 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Nkarta Reports First Quarter 2023 Financial Results and Corporate Highlights
11 May 23
EFFECT
Notice of effectiveness
8 May 23
CORRESP
Correspondence with SEC
3 May 23
S-3/A
Shelf registration (amended)
24 Apr 23
ARS
2022 FY
Annual report to shareholders
24 Apr 23
DEFA14A
Additional proxy soliciting materials
24 Apr 23
DEF 14A
Definitive proxy
24 Apr 23
PRE 14A
Preliminary proxy
14 Apr 23
8-K
Nkarta Announces Departure of Chief Financial & Business Officer
30 Mar 23
UPLOAD
Letter from SEC
21 Mar 23
S-3
Shelf registration
17 Mar 23
10-K
2022 FY
Annual report
16 Mar 23
8-K
Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
16 Mar 23
8-K
Regulation FD Disclosure
9 Jan 23
Latest ownership filings
4
James Trager
20 Jun 24
4
PAUL J HASTINGS
20 Jun 24
4
David Shook
20 Jun 24
4
Alicia J. Hager
20 Jun 24
4
Ralph Brandenberger
20 Jun 24
4
Simeon George
14 Jun 24
4
Ali Behbahani
14 Jun 24
4
Peter Kolchinsky
14 Jun 24
4
Zachary Scheiner
14 Jun 24
4
LEONE D PATTERSON
14 Jun 24
4
Michael Dybbs
14 Jun 24
4
Angela Thedinga
14 Jun 24
4
George Vratsanos
14 Jun 24
3
George Vratsanos
14 Jun 24
SC 13G/A
BlackRock Inc.
5 Apr 24
SC 13D/A
RA CAPITAL MANAGEMENT, L.P.
29 Mar 24
4
Peter Kolchinsky
29 Mar 24
SC 13D/A
Samsara BioCapital, L.P.
29 Mar 24
SC 13D/A
New Enterprise Associates 15, L.P.
28 Mar 24
SC 13D/A
GSK plc
28 Mar 24
4
Simeon George
28 Mar 24
4
PAUL J HASTINGS
5 Mar 24
4
Ralph Brandenberger
5 Mar 24
144
Notice of proposed sale of securities
4 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
144
Notice of proposed sale of securities
1 Mar 24
4
James Trager
14 Feb 24
144
Notice of proposed sale of securities
12 Feb 24
SC 13D/A
LSP 6 Holding C.V.
9 Feb 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
7 Feb 24
SC 13G/A
BlackRock Inc.
31 Jan 24
4
David Shook
18 Jan 24
4
James Trager
18 Jan 24
4
Ralph Brandenberger
18 Jan 24
4
PAUL J HASTINGS
18 Jan 24
4
Alicia J. Hager
18 Jan 24
SC 13G
Boxer Capital, LLC
18 Jan 24
4
David Shook
8 Jan 24
4
Ralph Brandenberger
8 Jan 24
4
James Trager
8 Jan 24